Dennis J. Henner
Director/Board Member chez The Reed Institute
Profil
Dennis Henner, PhD, has been Managing Director of Clarus since the firm’s inception in 2005.
Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm.
He has over 30 years of direct industry and investment experience within the healthcare sector.
From 1981 to 2001, Dr. Henner was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee.
Dr. Henner received his PhD from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
Dr. Henner is a member of the Board of Trustees of Reed College.
Postes actifs de Dennis J. Henner
| Sociétés | Poste | Début |
|---|---|---|
| The Reed Institute | Director/Board Member | - |
Anciens postes connus de Dennis J. Henner
| Sociétés | Poste | Fin |
|---|---|---|
| IMAGO BIOSCIENCES, INC. | Chairman | 11/01/2023 |
| FORTY SEVEN, INC. | Director/Board Member | 07/04/2020 |
Clarus Ventures LLC
 Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 30/11/2018 |
| AERIE PHARMACEUTICALS, INC. | Director/Board Member | 05/02/2015 |
| HUMANIGEN, INC. | Director/Board Member | 23/10/2013 |
Formation de Dennis J. Henner
| University of Virginia | Doctorate Degree |
| The Scripps Research Institute | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| Entreprise privées | 21 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Xcyte Therapies, Inc. | Health Technology |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Barrier Therapeutics, Inc.
 Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Barrier Therapeutics, Inc. discovers, develops, and commercializes pharmaceutical products in the field of dermatology in the United States. It markets Xolegel, Vusion, and Solage gels. The firm markets its products to dermatologists and other target physicians through sales force. The company was founded in 2001 and is headquartered in Princeton, NJ | Health Technology |
Cellerant Therapeutics, Inc.
 Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Pelikan Technologies, Inc.
 Pelikan Technologies, Inc. Medical SpecialtiesHealth Technology Pelikan Technologies, Inc. develops hand held diagnostic and monitoring devices. It combines novel and proprietary blood sampling and measurement techniques with state-of-the-art miniaturization and automation technologies to develop superior hand-held medical diagnostic and monitoring devices. The company was founded in 2001 and is headquartered in Palo Alto, CA. | Health Technology |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | Health Technology |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Health Technology |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Rinat Neuroscience Corp.
 Rinat Neuroscience Corp. BiotechnologyHealth Technology Rinat Neuroscience Corp. manufactures and markets drugs for treating neurological diseases. The company was founded by Arnon Rosenthal and Patrick G. Lynn on November 21, 2000 and is headquartered in South San Francisco, CA. | Health Technology |
Synergia Pharma, Inc.
 Synergia Pharma, Inc. Pharmaceuticals: OtherHealth Technology Synergia Pharma, Inc. develops clinical therapeutics. It offers therapeutics for the treatment of migraine and other neurological disorders. The company is headquartered in South San Francisco, CA | Health Technology |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | Finance |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Renato Corp.
 Renato Corp. Medical SpecialtiesHealth Technology Renato Corp. provides health diagnostic services. It provides non-invasive technologies through private health care firms and health and wellness centers. The company is headquartered in Miami, FL | Health Technology |
SFJ Pharmaceuticals, Inc.
 SFJ Pharmaceuticals, Inc. BiotechnologyHealth Technology SFJ Pharmaceuticals, Inc. develops pharmaceuticals drugs. It offers drugs for cancer, kidney, thyroid, leukemia, and lung cancer. The company was founded by Roberto DeBenedetto in January 2009 and is headquartered in Pleasanton, CA. | Health Technology |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA. | Health Technology |
